WAY 252623

Key Product Details

Product Description

WAY 252623 is a potent LXR agonist (IC₅₀ values are 24 and 179 nM for LXRβ and LXRα, respectively). Reduces total serum cholesterol and LDL cholesterol, and inhibits lesion growth in models of atherosclerosis. Increases ABCA1 and ABCG1 mRNA levels in rat peripheral blood cells. Orally bioavailable.

Licensing Information

Sold for research purposes under agreement from Pfizer Inc.

Product Specifications for WAY 252623

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for WAY 252623

The following data is based on the product molecular weight 422.78.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	2.37 mL	11.83 mL	23.65 mL
5 mM	0.47 mL	2.37 mL	4.73 mL
10 mM	0.24 mL	1.18 mL	2.37 mL
50 mM	0.05 mL	0.24 mL	0.47 mL

Calculators

Background References

References are publications that support the biological activity of the product.

• Quinet LXR ligand lowers LDL cholesterol in primates, is lipid neutral in hamster, and reduces atherosclerosis in mouse. J.Lipid Res. 2009 PMID: 19318684
• DiBlasio-Smith Discovery and implementation of transcriptional biomarkers of synthetic LXR agonists in peripheral blood cells. J.Transl.Med. 2008 PMID: 18925943

Product Documents for WAY 252623